Home / Peptides

Abaloparatide

Shop Abaloparatide
Code ths10 applied at checkout

Also called: Abaloparatide Treatment Protocol

By The Health Stacks Research TeamUpdated August 23, 2026

Abaloparatide is a man-made medicine used to help bones get stronger. It is an injection given just under the skin, usually in the stomach area. Doctors give this medicine to people who have osteoporosis, a condition where bones become weak and break easily. It is often used for women who have gone through menopause and are at a high risk for broken bones. This medicine is not a pill; it comes in a pen or a pre-filled device that makes it easy to inject the right amount.

This medicine works by copying a natural chemical in the body that helps control calcium. It tells the body to build new bone tissue. By doing this, it makes bones thicker and less likely to crack or break. It is part of a group of treatments that help build bone density, which is a measure of how strong the bones are. Using this medicine can help lower the chance of having painful fractures in the spine or other bones.

There are some important rules to follow with this medicine. It is usually taken every day for a limited time, often up to two years. You should not use it if your bones have been treated with radiation in the past. It is also important to make sure you get enough calcium and vitamin D while using it. Like all medicines, it can have side effects, so a doctor must check if it is safe for you. It is a strong option for people who really need to protect their bones.

ApprovedApproved by a regulator (e.g. FDA) for a specific medical use — the highest research-status tier. High confidence60–79 — backed by solid sources with good corroboration across multiple citations.

Benefits

What Abaloparatide Helps With

The benefits people report — backed by research.

Musculoskeletal (10)

Bone repair 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcReduces risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcReduces hip fracture risk when sequenced with antiresorptive therapy 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcTreats osteoporosis in postmenopausal women at high risk of fractures 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treats osteoporosis in men at high risk of fracture 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of post-menopausal osteoporosis 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of moderate to severe Rheumatoid Arthritis 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces risk of vertebral fractures in postmenopausal women with osteoporosis 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces risk of nonvertebral fractures in postmenopausal women with osteoporosis 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces risk of vertebral and nonvertebral fractures 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Cancer / tumor (2)

Treatment of metastatic urothelial carcinoma 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of metastatic squamous non-small cell lung cancer 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

More reported benefits (3)

Treatment of complex perianal fistulas in adult patients with Crohn’s disease 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of Haemophilia A 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of cutaneous, subcutaneous and nodal lesions in melanoma 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Free: The Peptide Stack Cheat-Sheet

You just read the research on Abaloparatide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.

No spam. Unsubscribe anytime.

How People Use It

1 reported routine — each line links to the source it came from.

Self-reported & vendor-suggested

Routines shared by users and sellers in forums and product pages — anecdotal, not tested in clinical trials. We show them for completeness, not as a recommendation.

SubQ

  • 80 mcg 60/100Rated 60/100Source typeSpecialist communityIndependent sources7Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source

mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.

Safety

Known Side Effects

Adverse effects reported in the research and by community use.

  • DizzinessModerate 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • Fast or pounding heartbeat and nauseaModerate 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • Headache and tirednessMild 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • Upper stomach pain or bloating and diarrheaMild 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • Pain in jointsMild 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • Injection site rednessMild 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • High blood calcium (hypercalcemia)Severe 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • Painful urination and blood in urineSevere 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • Osteosarcoma (bone cancer) riskSevere 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • lightheadednessModerate 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • and fainting (orthostatic hypotension)Moderate 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • painMild 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • or swellingMild 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medlineplus.gov
  • Injection site rednessMildReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ reference.medscape.com↗ rxlist.com
  • HypercalciuriaModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ reference.medscape.com↗ rxlist.com
  • Injection site edemaMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ reference.medscape.com
  • HeadacheMildReported in 3 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ reference.medscape.com↗ rxlist.com↗ rxlist.com
  • PalpitationsModerateReported in 3 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ reference.medscape.com↗ rxlist.com↗ rxlist.com
  • Orthostatic hypotensionModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ reference.medscape.com↗ rxlist.com
  • HypercalcemiaModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ reference.medscape.com↗ rxlist.com
  • Hypersensitivity and anaphylactic reactionsLifeThreateningReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ reference.medscape.com↗ rxlist.com
  • OsteosarcomaSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ reference.medscape.com
  • FatigueMildReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com↗ rxlist.com
  • Upper abdominal painMildReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com↗ rxlist.com
  • VertigoMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com
  • TachycardiaModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com
  • Injection Site Reactions (RednessMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com
  • UrolithiasisModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com
  • Hypercalciuria (Elevated calcium in the urine)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com
  • Injection site swellingMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com
  • Dizziness on standing (Orthostatic hypotension)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com
  • Hypercalcemia (High calcium in the blood)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com
  • Vertigo (Spinning sensation)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com
  • Fast heart rateModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com
  • EdemaMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com
  • Pain)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ rxlist.com
  • DizzinessMildReported in 4 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ reference.medscape.com↗ rxlist.com↗ rxlist.com↗ withpower.com
  • NauseaMildReported in 4 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ reference.medscape.com↗ rxlist.com↗ rxlist.com↗ withpower.com
  • Administration site reactionsMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com

Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.

Get Abaloparatide

Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.

Shop Abaloparatide
Code ths10 applied at checkout

Evidence

Research Citations (19)

Every claim above traces back to a source you can check — here are 19 of them.

  • Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.

    2023 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Abaloparatide

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • PubChem - Compound - Abaloparatide

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • "Tymlos- abaloparatide injection, solution"

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • "Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34)"

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).

    2017 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.

    2017 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.

    2016 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.

    2017 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • "One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats"

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.

    2017 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • "Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis"

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

    2015 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

Wondering how Abaloparatide pricing compares across suppliers? Our original market data shows the full picture.

See the State of the Peptide Market 2026 →

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.

No spam. Unsubscribe anytime.